ArticleMolecular pharmacology2019
Pyrimidinyl Biphenylureas Act as Allosteric Modulators to Activate Cannabinoid Receptor 1 and Initiate
Open access · hybridAbstract read
In one paragraph
Article in Molecular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Endocannabinoids at the synapse and beyond: implications for neuropsychiatric disease pathophysiology and treatment.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2023Review
- Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery.Trends in pharmacological sciences · 2021Review
- Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products.Journal of medicinal chemistry · 2021Review
- Molecular Mechanism and Cannabinoid Pharmacology.Handbook of experimental pharmacology · 2020Article
- Structural Optimization of the Diarylurea PSNCBAM-1, an Allosteric Modulator of Cannabinoid Receptor 1.Current therapeutic research, clinical and experimental · 2020Article
- Utilization of Biased G Protein-Coupled ReceptorSignaling towards Development of Safer andPersonalized Therapeutics.Molecules (Basel, Switzerland) · 2019Review
- Structural Insights into CB1 Receptor Biased Signaling.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Caitlin A D JaglaDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Caitlin E ScottDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Yaliang TangDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Changjiang QiaoDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Gabriel E Mateo-SemideyDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Guillermo A YudowskiDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Dai LuDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.).
Debra A KendallDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, Connecticut (C.A.D.J., C.E.S., Y.T., D.A.K.); Department of Anatomy and Neurobiology (G.E.M.-S., G.A.Y.) and Institute of Neurobiology (G.E.M.-S., G.A.Y.), University of Puerto Rico, San Juan, Puerto Rico; and Department of Pharmaceutical Sciences, Irma Lerma Rangel College of Pharmacy, Texas A&M Health Science Center, Kingsville, Texas (C.Q., D.L.) debra.kendall@uconn.edu.
Texas A&M Health Science Center · USUniversity of Connecticut · US
Funding
CB1 Allosteric Modulators: Molecular, Cellular and In Vivo PharmacologyR01DA039942 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI KINSEY, STEVEN G., LICHTMAN, ARON H · 2016 to 2020
$2.6MEndocytic mechanisms controlling functional selectivity of the CB1RR01DA037924 · NIDA · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SOSA, MARIA A · 2014 to 2018
$1.7MNIDA NIH HHS R01 DA037924NIDA NIH HHS R01 DA039942
Abstract
Cannabinoid receptor 1 (CB
Indexed as
Allosteric RegulationAllosteric SiteArachidonic Acidsbeta-Arrestin 1beta-Arrestin 2Cell LineCyclohexanolsEndocannabinoidsGlyceridesGTP-Binding ProteinsHEK293 CellsHumansPhenylurea CompoundsPhosphorylationPolyunsaturated AlkamidesProtein Binding1-(4-chlorophenyl)-3-(3-(6-pyrrolidin-1-ylpyridin-2-yl)phenyl)urea3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolanandamideArachidonic Acidsbeta-Arrestin 1beta-Arrestin 2CyclohexanolsEndocannabinoidsGlyceridesglyceryl 2-arachidonateGTP-Binding ProteinsPhenylurea CompoundsPolyunsaturated AlkamidesPyridinesReceptor, Cannabinoid, CB1Rimonabant
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.